AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Moderna, Inc.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company that specializes in research and development of therapeutics and vaccines for infectious, cardiovascular, immuno-oncology, and auto immune diseases based on messenger RNA (mRNA). Currently, MRNA has 15 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic and cancer vaccines, intratumoral immuno-oncology, and various therapeutics. It has also collaborated with various companies for the manufacturing of COVID-19 vaccines.
Why Should Investors Book Profit?
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
MRNA's share price has inclined 54.14% in the past six months and is currently leaning towards the lower band of the 52-week range of USD 119.33 to USD 497.49. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 157.60.
Considering the company's industry above leverage, weak liquidity profile, current valuation and associated risks. we recommend a "Sell" rating on the stock at the closing price of USD 172.54, up 2.29% as of April 04, 2022.
1 -Year Technical Price Chart (as of April 04, 2022). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.